Sensus Healthcare (SRTS) Earns News Sentiment Rating of 0.16

News stories about Sensus Healthcare (NASDAQ:SRTS) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Sensus Healthcare earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 45.6454660761641 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Sensus Healthcare (NASDAQ:SRTS) traded up $0.21 on Friday, hitting $5.58. The stock had a trading volume of 200 shares, compared to its average volume of 13,413. Sensus Healthcare has a 1 year low of $3.38 and a 1 year high of $6.25.

Separately, Maxim Group upped their price objective on Sensus Healthcare from $6.50 to $7.50 and gave the stock a “buy” rating in a report on Friday, November 3rd.

In related news, CEO Joseph C. Sardano sold 13,320 shares of the stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $6.00, for a total transaction of $79,920.00. Following the completion of the sale, the chief executive officer now directly owns 1,614,099 shares in the company, valued at approximately $9,684,594. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Joseph C. Sardano sold 9,625 shares of the stock in a transaction dated Monday, August 28th. The shares were sold at an average price of $6.00, for a total value of $57,750.00. Following the sale, the chief executive officer now owns 1,625,821 shares of the company’s stock, valued at $9,754,926. The disclosure for this sale can be found here. Insiders have sold a total of 84,735 shares of company stock valued at $508,410 over the last 90 days. 41.70% of the stock is currently owned by company insiders.

WARNING: This report was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.com-unik.info/2017/11/25/sensus-healthcare-srts-earns-news-sentiment-rating-of-0-16.html.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, formerly Sensus Healthcare, LLC, is a manufacturer of superficial radiation therapy devices. The Company designs, manufactures and markets medical devices specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy.

Insider Buying and Selling by Quarter for Sensus Healthcare (NASDAQ:SRTS)

Receive News & Ratings for Sensus Healthcare Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit